C 012 - Shanghai Pharmaceuticals Holding
Alternative Names: C-012 - Shanghai Pharmaceuticals Holding pipeline; C012Latest Information Update: 29 Aug 2023
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 24 Aug 2023 Phase-I clinical trials in Alzheimer's disease in China (unspecified route), prior to August 2023 (Shanghai Pharmaceuticals Holding pipeline, August 2023)